Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Receptor Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01698918
What this trial is testing

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Hormone Receptor Positive Breast Cancer
Novartis Pharmaceuticals 202
Not applicableStudy completedNCT01385280
What this trial is testing

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerProgesterone Receptor Positive TumorRecurrent Breast Cancer+2 more
University of Arizona 13
Early research (Phase 1)Study completedNCT02219789
What this trial is testing

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+3 more
Mayo Clinic 10
Testing effectiveness (Phase 2)Study completedNCT05963997
What this trial is testing

Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerBreast Cancer
Carrick Therapeutics Limited 49
Testing effectiveness (Phase 2)Study completedNCT00534417
What this trial is testing

Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Accelerated Community Oncology Research Network 41
Not applicableEnded earlyNCT00816582
What this trial is testing

PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 17
Testing effectiveness (Phase 2)Study completedNCT01216176
What this trial is testing

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Who this might be right for
Breast Cancer
Joyce Marie Slingerland, MD 71
Testing effectiveness (Phase 2)Looking for participantsNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Testing effectiveness (Phase 2)Study completedNCT02308020
What this trial is testing

Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain

Who this might be right for
Breast CancerNon-small Cell Lung CancerMelanoma+1 more
Eli Lilly and Company 162
Testing effectiveness (Phase 2)Active Not RecruitingNCT05625087
What this trial is testing

Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib

Who this might be right for
Breast Cancer Stage IV
UNICANCER 162
Large-scale testing (Phase 3)UnknownNCT03423199
What this trial is testing

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Who this might be right for
Breast Neoplasms
National Cancer Center, Japan 180
Not applicableUnknownNCT05559528
What this trial is testing

BRaziLian outcomE for metAStatic breasT Cancer

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IV
Hospital do Coracao 300
Testing effectiveness (Phase 2)Looking for participantsNCT05190094
What this trial is testing

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

Who this might be right for
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
International Cancer Research Group, United Arab Emirates 80
Post-approval studies (Phase 4)Active Not RecruitingNCT05161195
What this trial is testing

Roll-over Study to Allow Continued Access to Ribociclib

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 134
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Testing effectiveness (Phase 2)Ended earlyNCT00101062
What this trial is testing

Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
University of Medicine and Dentistry of New Jersey
Testing effectiveness (Phase 2)Study completedNCT01004081
What this trial is testing

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Who this might be right for
Breast Cancer
Biogen 54
Early research (Phase 1)Looking for participantsNCT07137416
What this trial is testing

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast Carcinoma+13 more
National Cancer Institute (NCI) 36
Early research (Phase 1)Study completedNCT01808040
What this trial is testing

A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer

Who this might be right for
Post Menopausal, Hormone Receptor Positive Breast Cancer
University of Wisconsin, Madison 8
Testing effectiveness (Phase 2)Ended earlyNCT00905021
What this trial is testing

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Baylor Breast Care Center 4
Next Page